New drug combo may shield kids from transplant complications
NCT ID NCT03924401
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding the drug abatacept to standard care can prevent graft-versus-host disease (GVHD) in children receiving stem cell transplants from unrelated donors. GVHD occurs when donor cells attack the patient's body, causing serious illness. The trial will enroll 30 children with non-cancerous blood disorders and follow them for up to 3 years to see if abatacept reduces GVHD without harming immune recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abatacept (Orencia)
What this could lead to
If successful, this could offer a safer way to prevent GVHD in children receiving stem cell transplants, reducing severe complications and improving recovery.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Adding abatacept could also increase infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Children's of Alabama
Birmingham, Alabama, 35233, United States
-
Childrens Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hackensack Meridian Health
Hackensack, New Jersey, 07601, United States
-
Nemours/Alfred I. DuPont Hospital for Children
Wilmington, Delaware, 19803, United States
-
Oishei Children's Hospital
Buffalo, New York, 14203, United States
-
University of Mississippi Medical Center, Children's Center for Cancer and Blood Disorders
Jackson, Mississippi, 39216, United States